Hims & Hers Health has seen a remarkable surge in its stock price, rising as much as 11% this week. This increase is part of a broader rally that has seen the stock climb over 125% since February’s lows. The rally began following an announcement from the FDA regarding a meeting to discuss easing regulations on peptides.
Significant Catalyst for Stock Increase
The FDA is set to evaluate potential changes to its regulations on 12 peptides. This consideration comes after Health Secretary Robert F. Kennedy Jr. advocated for easing restrictions. In 2023, the FDA imposed limitations on 19 peptides due to health concerns. However, the upcoming meeting signifies a possible shift that could benefit telehealth companies like Hims & Hers.
Peptide Advocacy by RFK Jr.
- Robert F. Kennedy Jr. has long supported peptide therapies.
- On Joe Rogan’s podcast, he shared personal benefits from peptide use.
- His advocacy aligns with Hims & Hers’ plans to expand its treatment offerings.
Company Positioning and Future Outlook
Hims & Hers, established for direct-to-consumer health solutions, has made significant strategic moves, especially in the realm of peptide manufacturing. In February 2025, they acquired a California-based facility, positioning themselves for potential growth in peptide therapies.
Historically, the company carved out a profitable niche by offering compounded GLP-1 weight-loss drugs amid shortages from major manufacturers like Novo Nordisk and Eli Lilly. While revenue surged by 59% to $2.35 billion in 2025, this strategy also exposed the company to regulatory challenges.
Recent Developments with Novo Nordisk
In 2025, Hims & Hers faced legal issues following a partnership collapse with Novo Nordisk over promotional practices. Following months of litigation, both companies agreed that Hims would focus on distributing Novo’s branded products.
As part of its evolving business strategy, Hims & Hers is now aiming to introduce a peptide-based product line within its longevity specialty. This is an essential move to maintain profit margins previously driven by GLP-1 products.
The Broader Market Context
The peptides market has exploded in popularity recently, becoming a significant wellness trend. Numerous compounds, including BPC-157 and GHK-Cu, have gained traction in clinics and through influencer marketing. This surge often occurs in a regulatory gray area, complicating the landscape further.
- Peptides have been promoted for various health benefits.
- The FDA’s 2023 restrictions on peptides formalized manufacturing limitations.
- American competitors like Eli Lilly have intensified market pressures on Novo Nordisk.
Market Dynamics and Competition
Currently, Novo Nordisk has seen a significant decline in market capitalization, losing $500 billion from its peak in 2024. The company faces stiff competition from both established drug manufacturers and emerging players like Hims & Hers.
As Hims & Hers prepares to navigate these market changes, the potential lifting of peptide regulations could open new avenues for growth and innovation in the health sector.
